Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-18
2011-01-18
Lucas, Zachariah (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S130100, C435S455000
Reexamination Certificate
active
07872110
ABSTRACT:
This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1/VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1/VK1#16, and clone 21 containing the recombinant genes B4DIVHv1/VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.
REFERENCES:
patent: 5912176 (1999-06-01), Wang
patent: 1 083 226 (2001-03-01), None
patent: 2-238883 (1990-09-01), None
patent: 6-125783 (1994-05-01), None
patent: 10-70986 (1998-03-01), None
patent: 10-155489 (1998-06-01), None
patent: WO 95/24483 (1995-09-01), None
patent: WO 98/52976 (1998-11-01), None
Li et al. (Biochemistry 2000. 39:6296-6309).
European Search Report for corresponding European application No. EP/03 78 6626 dated Jan. 16, 2007.
Weissenhorn, W. et al., Combinatorial Functions of Two Chimeric Antibodies Directed to Human CD4 and One Directed to the α-Chai of the Human Interleukin-2 Receptor,Gene1992, 121(2), 271-278.
Donahue, R.E. et al., Helper Virus Induced T Cell Lymphoma in Nonhuman Primates After Retroviral Mediated Gene Transfer,J. of Experimental Medicine1992, 176(4), 1125-1135.
Adair, F. Immunogenicity—The last hurdle for clinically successful therapeutic antibodies.BioPharm2000, (October), 42-46.
Altuvia, Y., Schueler, O. & Margalit, H. Ranking potential binding peptides to MHC molecules by a computational threading approach.J Mol Biol1995, 249(2), 244-250.
Bebbington, C.R. et al., High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.Biotechnology1992, 10(2), 169-175.
Belshe, R.B. et al., Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.JAMA1994, 272(6), 475-480.
Cheng-Mayer, C. et al., Biologic features of HIV-1 that correlate with virulence in the host. Science 1988, 240, 80-82.
Co, M.S. et al., Humanized antibodies for antiviral therapy.Proc Nat Aca Sci USA1991, 88, 2869-2873.
Coloma, M.J. et al., The role of carbohydrate in the assembly and function of polymeric IgG.Mol Immunol2000, 37(17), 1081-1090.
Cox, J.P.L. et al., A directory of human germ-line Vk segments reveals a strong bias in their usage.Eur J Immunol1994, 24(4), 827-836.
Daar, E.S. et al., High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.Proc. Nat. Acad. Sci. USA1990, 87(17), 6574-6578.
Desrosiers, R.C. et al., Vaccine protection against simian immunodeficiency virus infection.Proc Nat Acad Sci USA1989, 86, 6353-6357.
Eloit, M. Risks of virus transmission associated with animal sera or substitutes and methods of control.Dev Biol Stand1999, 99, 9-16.
Gardner, M. et al., Passive immunization of rhesus macaques against SIV infection and disease.AIDS Res Hum Retroviruses1995, 11(7), 843-854.
Gen. Clinical trials update.Genetic Engineering News2001, 21, 3.
Hanson, C.V. et al., Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing titers.J Clin Microbiol1990, 28(9), 2030-2034.
Hanson, C.V. Measuring vaccine-induced HIV neutralization: Report of a workshop.AIDS Res Hum Retroviruses1994, 10(6), 645-648.
Hieter, P.A. et al., Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments.Cell1980, 22(1 Pt 1), 197-207.
Hieter, P.A. et al., Evolution of human immunoglobulin kappa J region genes.J Biol Chem1982, 257(3), 1516-1522.
Hofmann-Lehmann, R. et al., Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficency virus challenge.J Virol2001, 75(16), 7470-7480.
Jameson, B.D. et al., Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein.Science1988, 240, 1335-1339.
Kabat, E.A. The Kabat database of sequences of proteins of immunological interest. immuno.bme.nwu.edu.
Keefer, M.C. et al., Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.AIDS Res Hum Retroviruses1994, 10(12), 1713-1723.
Kim, S.J. et al., Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure.Biotechnol Bioeng1998, 58(1), 73-84.
Leatherbarrow, R.J. et al, Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement Cl and interaction with human monocyte Fc receptor.Mol Immunol1985, 22(4), 407-415.
Li et al., Three-Dimensional Structures of the Free and Antigen-Bound Fab from Monoclonal Antilysozyme Antibody HyHEL-63†,‡.Biochemistry2000, 39, 6296-6309.
Ma, J.K-C., et al., Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants.Eur J Immunol1994, 24(1), 131-138.
Mascola, J.R. et al., Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.AIDS Res Hum Retroiruses1996, 12(14), 1319-1328.
Mascola, J.R.. et al., Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.J. Infect Dis1996, 173(2), 340-348.
Menossi, M. et al., Improved analysis of promotor activity in biolistically transformed plant cells.BopTechniques2000, 28(1), 54-58.
Mizushima, S. et al., pEF-BOS, a powerful mammalian expression vector.Nucleic Acids Res1990, 18(17), 5322.
Moore, J.P. AIDS vaccines: On the trail of two trials.Nature2002, 415, 365-366.
Moore, J.P. et al., Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.J. Virol. 2001, 75(13), 5721-5729.
Morrison, S.L. et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.Proc Nat Acad Sci USA1984, 81(21), 6851-6855.
Motto, M. et al., Genetic manipulations of protein quality in maize grain.Field Crops Researcch1996, 45, 37-48.
Mulligan, R.C. et al., Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome.Nature1979, 277(5692), 108-114.
Norderhaug, L. et al., Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells.J Immunol Methods1997, 204(1), 77-87.
Padlan, E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.Mol Immunol1991, 28(4-5), 489-498.
Page, M.J. & Sydenham, M.A. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells.Boptechnology1991, 9(1), 64-68.
Reichmann, L. et al., Reshaping human antibodies.Nature1988, 332, 323-327.
Reimann, K.A. et al., A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.AIDS Res Hum Retro
Lynn Shugene
Wang Chang Yi
Boesen Agnieszka
Locke Lord Bissell & Liddell LLP
Lucas Zachariah
Schurter Brandon T.
United Biomedical Inc.
LandOfFree
Deimmunized monoclonal antibodies for protection against HIV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Deimmunized monoclonal antibodies for protection against HIV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deimmunized monoclonal antibodies for protection against HIV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664283